Facebook
Twitter
LinkedIn
Forward
Advances in Treatment for Retinal Disease: What Optometrists Need to Know (COPE-Approved CE Webcast)
Activity Description and Purpose
This is a 4-part series of 15-minute discussions that will help optometrists who care for patients with neovascular age-related macular degeneration and diabetic macular edema better understand how to address the burden patients face, current treatment options, the need for longer-acting treatments, and best practices. The fourth module features an interview with a patient to help clinicians put these concepts into a real-life clinical context. The modules can be taken individually in any order and are each accredited for 0.25 COPE CE credit.
Target Audience
This educational activity is intended for optometrists.
Learning Objectives
After completing this activity, participants will be better able to:
- Describe efficacy/safety data on treatment with extended-release anti–vascular endothelial growth factor for neovascular age-related macular degeneration
- Review clinical trial data for approved agents with a dual mechanism of action for neovascular age-related macular degeneration and diabetic macular edema
- Illustrate how addressing treatment burden can be incorporated into patient encounters
Faculty
 | Mohammad Rafieetary, OD, FAAO, FORS |
 | Arshad M. Khanani, MD, MA, FASRS
|
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
Arshad M. Khanani, MD, MA, is a consultant for Alimera Sciences, Allergan, Apellis Pharmaceuticals, AsclepiX Therapeutics, Aviceda Therapeutics, Bausch & Lomb Incorporated, Broadwing Bio, Chengdu Kanghong Pharmaceutical Group Co, Ltd, Cholgene Therapeutics Inc, F. Hoffmann-La Roche Ltd, 4DMT, Gemini Therapeutics, Genentech, Inc, Graybug, Inc, Gyroscope, Iveric Bio, Inc, Janssen Pharmaceuticals, Inc, Kato Pharmaceuticals, Kodiak Sciences Inc, Novartis Pharmaceuticals Corporation, Oculis, Opthea, Oxurion NV, PolyPhotonix, Regeneron Pharmaceuticals, Inc, Regenxbio Inc, Retrotope Inc*, Thea Pharmaceuticals Limited, and Unity Biotechnology; is on the speakers bureau for Allergan, Genentech, Inc, and Novartis Pharmaceuticals Corporation; is a contracted researcher for Apellis Pharmaceuticals, F. Hoffmann-La Roche Ltd, 4DMT, Gemini Therapeutics, Genentech, Inc, Gyroscope, Iveric Bio, Inc, Kodiak Sciences Inc, NGM Bio, Novartis Pharmaceuticals Corporation, Oculis, Opthea, Oxurion NV, Regenxbio Inc, and Unity Biotechnology; and has stock options in Aviceda Therapeutics, PolyPhotonix, and Retrotope Inc*.
Mohammad Rafieetary, OD, is an advisory board member of Apellis Pharmaceuticals, Cardinal Health, Heidelberg Engineering GmbH, Iveric Bio, Inc, Notal Vision, Optos, and Regeneron Pharmaceuticals, Inc; and is on the speakers bureau for Heidelberg Engineering GmbH, Notal Vision, Optos, Regeneron Pharmaceuticals, Inc, and Spark Therapeutics, Inc.
* The financial relationship existed during the last 24 months but has now ended
Planners, Managers, and Writers
Carrie Allen, PharmD, BCPP, BCPS, MedEdicus Content Manager for this activity, was previously employed by CVS within the past 2 years, but that relationship has ended.
Other MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
Accreditation Statement
COPE approved for 1.0 CE credit for optometrists.
COPE Course Category: Treatment & Management of Ocular Disease
Administrator: 
Disclosure of Commercial Support
This continuing education activity is supported through an educational grant from Genentech, Inc.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Genentech, Inc.
This CE activity is copyrighted to MedEdicus LLC ©2022. All rights reserved. 282
Available Credit
- 1.00 COPE